Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors

Inclusion Criteria: * Age \>18 years. * Dated and signed written informed consent. * Histologically progressive mRCC or other advanced refractory histologically or cytologically confirmed solid tumors. In mRCC situation, only patients who have received no prior therapy or who have failed only one prior systemic therapy (except tyrosine kinase inhibitors) are allowed; for patients with other advanced refractory solid tumors, no more than three prior systemic therapy regimens (except tyrosine kinase inhibitors) are permitted. * ECOG performance status of 0 or 1. * At least one measurable site of disease as defined by RECIST criteria 1.1. based on investigator's assessment. * Adequate bone marrow function: absolute neutrophil count \>=1.5 x 109/L, platelet count \>= 100 x 109/L, and hemoglobin \>= 9 g/dL. * Adequate liver function: AST/ALT \<= 2 x upper limit of normal (ULN) and total bilirubin in the normal values. * Adequate coagulation function: prothrombin time (PT) or international normalized ratio (INR) \<=1.2 x ULN and activated partial thromboplastin time (APTT)\<=1.2x ULN. * Adequate renal function: serum creatinine ≤ 1.5 mg/dL (133 µmol/L) or, if greater than 1.5 mg/dL: calculated creatinine clearance ≥ 50 mL/min. * Absence of proteinuria confirmed by urinary dipstick test. If the dipstick test is twice positive, proteinuria will be quantified on a complete 24h urine sample: urine protein value must be \<1 g /L. * Ability to swallow and retain oral medication. * Adequ…